Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

SON-1210 elicited no serious adverse events in repeat, subcutaneous dosing in a GLP toxicology studySON-1210 was well-tolerated using dosing levels at least 50x higher than the highest anticipated human clinical dose levelData show controlled …